The FDA has approved the KXL System and two photoenhancers for corneal collagen cross-linking treatment of progressive keratoconus, according to a press release from Avedro.The photoenhancers are Photrexa 0.146%, a riboflavin 5’-phosphate solution, and Photrexa Viscous 0.146%, a riboflavin 5’-phosphate in 20% dextran ophthalmic solution.
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release first quarter 2016 financial results after the market close on Tuesday, May 3, 2016. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 3, 20
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today the completion of the treatment period in the ongoing Phase 2b/3 clinical trial, the S.E.A.T.T.L.E. study, of the investigational visual cycle modulator emixustat hydrochloride (emixustat). The study enrolled 508 patients with geographi
Status: Recruiting,
Condition Summary: Dry Eye Disease
The riboflavin ophthalmic solution, once irradiated with ultraviolet A light, treats sight-threatening keratoconus with corneal collagen crosslinking. FDA Approvals
The American Society of Ophthalmic Plastic and Reconstructive Surgery announced in a press release it has named Robert Alan Goldberg, MD, as president.Goldberg, professor of ophthalmology at the David Geffen School of Medicine and UCLA and chief of orb…